---
document_datetime: 2026-01-13 10:15:29
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/besremi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: besremi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2999898
conversion_datetime: 2026-01-14 07:18:53.329972
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Besremi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 09/01/2026                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000314219                     | PRODUCTS - C.I.z Other variation - Accepted C.I.z - To update the 'Instructions for use' in the Package Leaflet to more precisely adapt the presentation of the dosing scheme including the 5µg increment steps, implemented in procedure EMEA/H/C/004128/II/0033/G, for the Besremi 250 µg / 0.5 mL pen presentations. In addition, The MAH took the opportunity to delete the reference to a potential pack size including six co-packed needles from English and Lithuanian 'Instructions for use' in the Package Leaflet text for the Besremi 500 µg / 0.5 mL pen. Finally, correction of a typographical error in the Norwegian 'Instructions for use' in the Package Leaflet text for the Besremi 250 µg / 0.5 mL pen   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000295474 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z - to update the RMP to revise the Post-Authorisation Safety Study (PASS, category 3) milestone dates. The proposal date for the Final report has changed from 'Q4 2025' to 'Q1 2026.'                                                                                                                                                                                                                                                                                    | 21/10/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000277854   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to correct Table 1 in Section 4.8 Undesirable effects due to an error in the statistical report. In addition, the MAH took the opportunity to introduce editorial changes to the PI, and DE, DK, NL PIs.                                                                                                    | 04/09/2025   |     | SmPC   | Not applicable.   |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|--------|-------------------|
| Variation type II / EMA/VR/0000269531   | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of | 04/09/2025   | N/A |        |                   |

<div style=\"page-break-after: always\"></div>

|                                       | specification limits - Accepted                                                                                                                                                                         |            |     |    |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Variation type IB / EMA/VR/0000246850 | This was an application for a group of variations. B.IV.1.a Addition or replacement of a device which is not an integrated part of the primary packaging - B.IV.1.a.1 Device with CE marking - Accepted | 29/03/2025 |     | PL |
| Variation type IA / EMA/VR/0000261647 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                          | 25/03/2025 | N/A |    |
| Variation type IB / EMA/VR/0000258987 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                           | 25/03/2025 | N/A |    |